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Background. The wide use of antibiotics for treatment of exacerbations of chronic obstructive pulmonary
disease (COPD) lacks evidence. The efficacy is debatable, and bacterial involvement in exacerbation is difficult to
verify. The aim of this prospective study was to identify factors that can help to estimate the probability that a
microorganism is involved in exacerbation of COPD and, therefore, predict the success of antibiotic treatment.
Methods. Clinical data and sputum samples were obtained from 116 patients during exacerbation of COPD.
Bacterial infection was defined by the abundant presence of 1 potential pathological microorganism in relation
to the normal flora in sputum.
Results. Of 116 exacerbations, 22 (19%) had bacterial involvement. The combination of a negative result of
a sputum Gram stain, a relevant nonclinical decrease in lung function (compared with baseline measurements),
and occurrence of !2 exacerbations in the previous year were 100% predictive of a nonbacterial origin of the
exacerbation. The presence of all 3 of these clinical characteristics yielded a positive predictive value of 67% for
a bacterial exacerbation.
Conclusions. Patients presenting with an exacerbation who have a negative result of a sputum Gram stain,
do not have a clinically relevant decrease in lung function, and who have not experienced !2 exacerbations of
COPD in the previous year do not require antibiotic treatment. A treatment protocol taking into account these
variables might lead to a 5%–24% reduction in unnecessary treatment with antibiotics, depending on actual
prescription rates.
The clinical course of chronic obstructive pulmonary
disease (COPD) is, despite optimal pharmacological
treatment, one of gradual progressive impairment, which
may lead to substantial functional limitations and, even-
tually, to respiratory failure [1, 2]. Morbidity and mor-
tality among patients with COPD are, for the most part,
related to acute exacerbations of COPD [3], which occur
an average of 1–3 times per year [4]. The definition of
an acute exacerbation of COPD is a major point of crit-
icism in many of the studies dealing with that issue [5,
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6]. Recently, an acute exacerbation of COPD was rede-
fined as a sustained worsening of a patient’s condition
from a stable state (beyond normal day-to-day varia-
tions) that is acute in onset and that may warrant ad-
ditional treatment in a patient with underlying COPD
[6, 7].
The etiology of exacerbations is heterogeneous and
still under discussion. Recent studies have stated that at
least one-third of COPD exacerbations may be triggered
by viral infections [8, 9]. Undoubtedly, bacteria also play
a role in exacerbations of COPD [10]. It is estimated
that up to 50% of sputum samples obtained during ex-
acerbation of COPD yield relevant bacteria [11–14].
The management of exacerbations is usually empir-
ical and includes therapy with corticosteroids and often
antibiotics. Recent studies have shown that a course of
oral corticosteroids is superior to placebo for the treat-
ment of exacerbations in hospitalized patients and out-
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patients [15, 16]. However, there is a lack of evidence favoring
the wide use of antibiotics for treatment of COPD exacerba-
tions, and the efficacy of this treatment is debatable. It is dif-
ficult to predict a bacterial cause of an exacerbation of COPD
[17, 18].
For a physician, it is hard to decide, on clinical grounds,
whether to prescribe antibiotics to a patient with an exacer-
bation of COPD at the time of presentation. Recently Ewig et
al. [18] proposed that antibiotic treatment of acute exacerba-
tions of COPD should only regularly be administered to pa-
tients who meet 2 of the Winnipeg criteria for increased
dyspnea, sputum volume, and purulence [19, 20], patients with
4 exacerbations during the past year and/or significant car-
diopulmonary comorbidity [21], and patients presenting with
severe airway obstruction or severe respiratory failure requiring
ventilatory support [18]. Evidence for these criteria and the
diagnostic value of many diagnostic tools (e.g., sputum pu-
rulence, Gram stain, radiography, determination of C-reactive
protein levels, and determination of lung function parameters)
for predicting a bacteriological origin of exacerbations are still
under debate [13, 17, 20, 22–27]. Furthermore, microbiological
analyses of sputum samples are often not performed, and mi-
crobiological criteria for the interpretation of the results are
often poorly defined and are reported to have had little impact
on treatment, because the test results are not available at pre-
sentation of the exacerbation [28].
The aim of this prospective study was to identify predictive
factors for exacerbations of COPD caused by bacteria for which
treatment with antibiotics is indicated by correlating clinical
signs, symptoms, and rapidly available laboratory data on pre-
sentation of an acute exacerbation of COPD and by using clear-
cut definitions for interpretation of bacterial culture results.
PATIENTS AND METHODS
Patients. From May 1999 through March 2000, patients were
recruited from the outpatient pulmonary clinic of the Medisch
Spectrum Twente, a 1150-bed teaching hospital in Enschede,
The Netherlands. To be eligible for the study, the patients had
to have met the following criteria: (1) a clinical diagnosis of
stable COPD, as defined by American Thoracic Society criteria
[29]; (2) no history of asthma; (3) no exacerbation or ante-
cedent use of an antibiotic in the month prior to enrollment;
(4) status as a current or former smoker; (5) age of 40–75 years;
(6) baseline prebronchodilator forced expiratory volume in 1
s (FEV1) of 25%–80% of predicted value; (7) prebronchodilator
ratio of FEV1 to inspiratory vital capacity (IVC) of 60%; (8)
reversibility of FEV1 after inhalation of 80 mg of ipratropium
bromide (via a metered-dose inhalator), with an aerochamber
of 12% of the predicted value [30]; (9) total lung capacity
(TLC) greater than the predicted ; (10) noTLC (1.64 SD)
maintenance treatment with oral steroids or antibiotics; (11)
no medical condition associated with a low survival rate or
serious psychiatric morbidities (e.g., cardiac insufficiency and
alcoholism); (12) and absence of any other active lung disease
(e.g., sarcoidosis). Use of such medications as nasal cortico-
steroids and theophyllines, chronic use of acetylcysteine, and
all other use of bronchodilators was allowed.
The hospital’s medical ethics committee approved this study.
All patients provided written informed consent.
Study design. This study was part of a randomized, dou-
ble-blind, single center study that investigated the role of in-
haled corticosteroids in COPD [31]. From this study, patients
were recruited at presentation of the first exacerbation of
COPD. Any time that patients experienced worsening of their
respiratory symptoms, they were instructed to contact the study
personnel by telephone. They were subsequently invited to visit
the outpatient department within 12 h for spirometry mea-
surements, sputum sample collection, and consultation with
one of the study physicians. Lung function data and sputum
samples were collected. On a standardized exacerbation report,
staff doctors registered the presence of “major” symptoms (i.e.,
increase in dyspnea, cough, increase in sputum volume, and
sputum purulence) and “minor” symptoms (i.e., nasal dis-
charge/congestion, wheeze, sore throat, cough, fever, and need
of extra bronchodilator) [19] and the treatment prescribed.
Furthermore, the study physician reported his/her clinical judg-
ment about the severity of the exacerbation (judged as no ex-
acerbation or mild, moderate, or severe exacerbation) before
being informed of the results of the lung function tests and
Gram stains.
Clinically, an exacerbation was defined as a worsening of
respiratory symptoms that led the patient to contact the study
office. Classification of the type of an exacerbation was ex-
pressed using the Anthonisen score [19]. Lung function was
measured by spirometry. Well-trained lung function technicians
performed spirometry on water-sealed spirometers, in accor-
dance with standardized guidelines. FEV1 and IVC were mea-
sured until 3 reproducible recordings (!5% difference) were
obtained. The highest values were used for analyses. A clinically
relevant decrease in FEV1 was defined as a decrease of 112%
and 200 mL from the baseline level [32]. The most recent result
of the lung function test in stable state was used as a baseline
value to calculate the decrease in FEV1 at exacerbation. Body
mass index (BMI) was computed as kg/m2. In patients with
COPD, a poor nutritional status is indicated by a BMI of !22
kg/m2.
Sputum samples. The laboratory technicians processing
the sputum samples were unaware of the clinical condition of
the patients. Spontaneously expectorated sputum was collected
in sterile vials and processed in the laboratory within 4 h after
collection. Total sputum samples were homogenized by incu-
bation at 37C for 15 min with an equal volume of 0.1% di-
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Table 1. Baseline characteristics of patients, stratified by bac-
terial exacerbation status, according to the primary criteria for
bacterial origin of an exacerbation of chronic obstructive pul-
monary disease (COPD).
Characteristic
Patients with
bacterial
exacerbation
of COPD
Patients with
nonbacterial
exacerbation
of COPD
No. of patients 22 94
Age, mean years  SD 64  6 64  7
Male sex, % of patients 82 78
Mean no. of exacerbations in
preceding yearSD 2.3  2.2 1.4  1.8
Smoking status, % of patients
Ex-smokers 73 65
Current smokers 27 35
Lung function after bronchodilation,a
mean  SD
FEV1, L 1.6  0.5 1.6  0.5
Percentage of predicted FEV1 value 54  16 55  15
NOTE. FEV1, forced expiratory volume in 1 s.
a Compared with baseline values.
Table 2. Clinical characteristics of patients, stratified by bac-
terial exacerbation status, according to the primary criteria for
bacterial origin of an exacerbation of chronic obstructive pul-
monary disease (COPD).
Characteristic
Patients with
bacterial
exacerbation
of COPD
Patients with
nonbacterial
exacerbation
of COPD
No. of patients 22 94
Lung function after bronchodilation
FEV1 at exacerbation, mean LSD 1.4  0.5 1.5  0.5
Relevant decrease in FEV1, % 57
a 31b
Anthonisen type 1 exacerbation 46 37
Clinical judgment of moderate/
severe exacerbation 36 16
Increased sputum volume 81a 68c
Purulent sputum 41 32c
Fever 18 21d
Nasal discharge 46 46c
Sore throat 41 27c
Positive Gram stain result 59 26
BMI of !22 kg/m2 5 10
Fluticasone propionate use
at exacerbation 68 63
NOTE. Data are percentage of patients, unless otherwise indicated. BMI,
body mass index; FEV1, forced expiratory volume in 1 s.
a Based on information from 21 patients.
b Based on information from 91 patients.
c Based on information from 93 patients.
d Based on information from 92 patients.
thiothreitol. Gram-stained sputum samples were examined mi-
croscopically and had to contain !105 epithelial cells per mL1
(i.e., !1 epithelial cell per high-power field) to be considered
representative bronchial samples. Polymorphonuclear cell
count was not one of the criteria. A positive Gram stain result
suggested the presence of a single pathogenic organism or dem-
onstrated the abundant presence of a potentially pathogenic
microorganism (PPM), compared with the background flora
(i.e., 11-log difference). Appropriate dilutions of homogenized
sputum samples were placed on blood, chocolate, cysteine lac-
tose electrolyte deficient medium, and Sabouraud agar plates.
Bacterial and mycological isolation and identification were per-
formed with the use of standard techniques of the American
Society for Microbiology [33]. Streptococcus pneumoniae, Hae-
mophilus influenzae, Moraxella catarrhalis, Pseudomonas aeru-
ginosa, and Staphylococcus aureus were considered to be PPM.
Other bacterial species were classified as normal flora (non-
PPM).
A bacterial exacerbation was defined in 2 ways. First, it was
defined in accordance with the primary criteria used for pneu-
monia [33]: by the abundance of 1 PPM (i.e., 1107 colony-
forming units [cfu]/mL) in excess (1 log) of the normal mi-
crobiological flora in sputum. Second, because these criteria
have been under debate with regard to exacerbations of COPD,
a secondary analysis was performed using the following sec-
ondary criteria for bacterial exacerbation of COPD: PPMs were
regarded as significant if they reached a level of absolute growth
of 1106 cfu/mL , except for S. pneumoniae, for which a level
of growth of 1105 cfu/mL was deemed sufficient, irrespective
of the presence of non-PPMs [13].
Statistical analyses. Baseline characteristics are reported
as for continuous variables or as percentages formeans SD
categorical or dichotomous variables stratified by presence or
absence of bacterial exacerbation. To avoid dependency between
exacerbations, we included only the first exacerbation during
which a sputum sample was obtained.
First, univariate logistic regression analyses were performed
to identify the subset of independent variables that were as-
sociated with a bacterial exacerbation. The a priori list of po-
tential predicting variables included Gram stain (positive vs.
negative), relevant decrease of FEV1, clinical judgment (mod-
erate or severe exacerbation vs. mild or no exacerbation), BMI
(22 vs. 122), number of exacerbations in the year preceding
the study (0–1 vs. 2), sex, smoking status, fever, sore throat,
nasal discharge, increase in sputum volume, sputum color,
dyspnea, and Anthonisen score (type 1 vs. other) [19]. Only
those variables with a significance level of were con-P .15
sidered to be candidate variables for the multivariate logistic
regression analysis. For the development of the predictive
model, we started with all candidate variables (full model).
Subsequently, we eliminated the variables step by step, starting
with the highest P value, until the model fit decreased signif-
icantly (based on likelihood-ratio test results).
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Table 3. Positive and negative predictive values for the 3 variables (and combinations of the 3
variables), according to the primary criteria for bacterial origin of an exacerbation of chronic
obstructive pulmonary disease, in the final multivariate logistic regression model.
Variable
Positive predictive
value, % (95% CI)
Negative predictive
value, % (95% CI)
Positive Gram stain result 35 (20–50) 89 (82–96)
Relevant decrease in FEV1
a 30 (16–44) 88 (80–96)
No. of exacerbations in the year preceding the study 32 (19–45) 90 (83–97)
Positive Gram stain result, relevant decrease in FEV1, and
no. of exacerbations in the year preceding the study 67 (36–97) 100
Positive Gram stain result and relevant decrease in FEV1 50 (26–75) 92 (69–115)
Positive Gram stain result and no. of exacerbations in
the year preceding the study 63 (49–78) 97 (93–101)
Relevant decrease in FEV1 and no. of exacerbations in
the year preceding the study 43 (27–59) 89 (81–97)
NOTE. FEV1, forced expiratory volume in 1 s.
a A clinical relevant decrease in FEV1 was defined as a decrease of 112% and of 200 mL, compared with the
baseline value.
Figure 1. Receiver operating characteristic curves for the model with
all 3 predictors (Gram stain result, decrease in the forced expiratory
volume in 1 s, and number of exacerbations in preceding year; solid line)
and for the model with Gram stain result and number of exacerbations
in the preceding year (dotted line).
Finally, we calculated positive and negative predictive values
for the variables in the final multivariate regression model (sep-
arately and combined). We plotted receiver operating charac-
teristic (ROC) curves and estimated the area under the curve
(AUC) and 95% CIs. The AUC was used to provide an overall
estimate of the diagnostic performance of the prediction rule
to differentiate bacterial exacerbations from nonbacterial
exacerbations.
For the secondary analysis, the same statistical procedure was
applied. In this analysis, only the microbiological criterion for
a bacterial exacerbation was changed, as described above.
RESULTS
In total, 123 sputum samples were obtained at the time of
presentation with the first acute exacerbation of COPD. For
116 of these 123 exacerbations, the presence of a bacterial in-
fection could be analyzed. According to the primary criteria
used for pneumonia [33], 22 patients (19%) had a bacterial
exacerbation, and 94 patients (81%) did not. Table 1 shows
the baseline characteristics of the patients stratified by presence
or absence of bacterial exacerbation.
The following variables were associated with a bacterial ex-
acerbation according to the primary criteria in univariate analy-
sis: Gram stain result, relevant decrease in the FEV1, clinical
judgment, BMI, and number of exacerbations in preceding year.
These were included in a multivariate logistic regression model
(table 2). This analysis revealed that Gram stain result, decrease
in the FEV1, and number of exacerbations in preceding year
together best predict the existence of a bacterial exacerbation
(final model). Table 3 shows the positive and negative predictive
values of all combinations of these variables, together and sep-
arately. The positive predictive value for these variables together
is 67% (95% CI, 36%–97%), and the negative predictive value
if all 3 are absent is 100%. The second best combination (Gram
stain result and number of exacerbations in the year preceding
the study) reduced the positive predictive value to 63% and
the negative predictive value to 97%. The ROC curves for all
3 variables and the second best combination (Gram stain and
number of exacerbations in the year preceding the study)
yielded AUCs of 0.78 (95% CI, 0.68–0.88) and 0.76 (95% CI,
0.64–0.87), respectively (figure 1).
Analysis of the prescription of antibiotics by chest physicians
showed that antibiotic therapy was appropriate for only 14
(28%) of 50 recipients with exacerbations, as determined on
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Table 4. Prescription of antibiotics, in relation to a bacterial
exacerbation of chronic obstructive pulmonary disease (COPD),
according to primary criteria.
Therapy
No. (%) of patients
Total
no. of
patients
(n p 116)
Bacterial
exacerbation
of COPD
(n p 22)
Nonbacterial
exacerbation
of COPD
(n p 94)
Antibiotics received 14 (64) 36 (38) 50
No antibiotics received 8 (36) 58 (62) 66
Table 5. Implications of the combination of all 3 predictors for
antibiotic use.
Variables
No. (%) of patients
Total
no. of
patients
Bacterial
exacerbation
of COPD
Nonbacterial
exacerbation
of COPD
Three predictors present 6 (67) 3 (33) 9
Three predictors absenta 0 (0) 28 (100) 28
Otherb 16 (20) 63 (80) 79
All 22 (19) 94 (81) 116
NOTE. The 3 predictors were positive Gram stain result, relevant decrease
in forced expiratory volume in 1 s, and2 exacerbations in the year preceding
the study.
a Negative Gram stain result, no relevant decrease in forced expiratory vol-
ume in 1 s, and !2 exacerbations in the year preceding the study
b Patients with 1 or 2 positive predictors.
the basis of our microbiological criteria for a bacterial exac-
erbation. Moreover, 8 (36%) of 22 bacterial exacerbations were
not treated with antibiotics (table 4).
If the variables of negative Gram stain result, no reduction
in FEV1, and 0–1 exacerbations in the preceding year were taken
into account, 11 (40%) of 28 exacerbations were found to have
been unnecessarily treated with antibiotics. Table 5 shows the
implications for the combinations of all 3 of these predictors
for antibiotic therapy.
Only 35% of those with positive results of Gram stains of
sputum samples obtained at presentation for the exacerbation
had a positive culture result. Furthermore, for 59% of those
with positive sputum culture results, the results of Gram stains
were also positive.
The prevalence of bacterial exacerbation increased from 19%
using the primary criteria to 46% (56 of 123 cases) using the
secondary criteria. Forty percent of these so-classified bacterial
infections occurred in individuals who also had a positive Gram
stain result. The variables significantly associated with a bac-
terial exacerbation in univariate analysis were Gram stain result,
clinical judgment, BMI, number of exacerbations in preceding
year, sputum color, and increase in sputum volume. These were
included in a multivariate logistic regression model. This analy-
sis revealed that Gram stain result and number of exacerbations
in preceding year together best predicted the existence of bac-
terial exacerbation according to the less-strict criteria. The pos-
itive predictive value of these variables together is 75% (95%
CI, 54%–96%), and the negative predictive value is 62% (95%
CI, 55%–69%).
DISCUSSION
The most common decision a doctor has to make when treating
a patient with an acute exacerbation in COPD is whether to
prescribe antibiotic therapy. We are not aware of a study com-
bining the aforementioned clinical signs, symptoms, and rap-
idly available laboratory data at first presentation as predictors
of an acute bacterial exacerbation of COPD. This study, which
investigated the clinical predictors of bacterial involvement in
exacerbations of moderate-to-severe COPD, revealed 4 impor-
tant new findings. First, we found a 100% negative predictive
value for nonbacterial involvement with a combination of a
negative result of a sputum Gram stain, a clinically nonrelevant
decrease in lung function (compared with baseline measure-
ments), and !2 exacerbations in the previous year. Second, the
best positive predictive value for a bacterial exacerbation of
COPD was a combination of a positive result of a sputum
Gram stain, a clinically relevant decrease in lung function, and
2 exacerbations of COPD in the previous year. Third, the
classic Anthonisen type I criteria (dyspnea, sputum volume,
and sputum purulence) were not predictors of bacterial origin
of an exacerbation. Finally, using the clear-cut definition of
bacterial infection from the American Society for Microbiology
criteria for pneumonia in defining bacterial origin of COPD
exacerbations [33], this study found that only 19% of the pri-
mary exacerbations originated with a bacterial infection.
It takes ∼45 min to obtain the results of a Gram stain and
basic spirometry. The 100% negative predictive value for a
nonbacterial origin of an exacerbation, which occurred in 25%
of all exacerbations in this study, might help physicians decide
whether to forego what may be unnecessary treatment. Also
the combination of the variables negative results of a sputum
Gram stain and !2 exacerbations in the previous year results
in a high negative predictive value and a comparable diagnostic
performance, as estimated by the AUC. This study demon-
strated once again that more-objective criteria for use of an-
tibiotic therapy in exacerbations of COPD are needed to prevent
overuse of antibiotics [25, 34].
In our population, ∼40% of the exacerbations of moderate-
to-severe COPD were treated with antibiotics, a figure that
represents the Dutch practice fairly well. Use of our prediction
rule would reduce this percentage to 35%, an absolute reduc-
tion of 5%. Because regular prescription rates for these patients
in other countries are much higher, the potential savings made
by applying this prediction rule might increase to 24% in sit-
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Figure 2. Potential savings in the rate of antibiotic treatment for different prescribing prevalences
uations in which every exacerbation of COPD is treated with
antibiotics (figure 2).
The positive predictive value for a bacterial exacerbation of
these variables (positive result of a sputum Gram stain, a rel-
evant decrease in lung function, and 2 exacerbations in the
previous year) was 67%, raising the likelihood of a bacterial
exacerbation (19%) by 48%. Unfortunately, this only pertains
to 8% of the exacerbations.
The yield of Gram stains has proven to be highly dependent
on whether a skilled investigator applies strict criteria [35]. In
a study of nosocomial pneumonia, the negative predictive value
for Gram stains of endotracheal aspirate specimens was re-
ported to be as high as 94%, which is comparable to the results
we obtained using the primary exacerbation criteria [36]. Sim-
ilar to other studies [23], in our study, the presence of a positive
sputum Gram stain result at presentation does not predict a
positive culture result very well; on the other hand, a positive
culture result was not a strong predictor of a positive sputum
Gram stain result. Prior measurements of lung function are
reported to be useful for comparison with measurements made
during an acute exacerbation [1], but the importance of change
from baseline spirometry findings as a tool for predicting a bac-
terial cause of an exacerbation has not yet been demonstrated.
Historically, on the basis of the results of the Anthonisen
study, patients presenting with type I criteria (dyspnea and
change in sputum characteristics [increased volume or puru-
lence]) are almost always treated with antibiotics [19]. Although
these criteria define a type of exacerbation, they do not define
its (bacterial) etiology. We found no association between bac-
terial exacerbations and Anthonisen type 1 exacerbations.
Because we included patients with less severe COPD, com-
pared with the Anthonisen study, the prevalence of PPMs dur-
ing the exacerbation is expected to be lower [13] and might
explain the lack of the aforementioned association in our study
between bacterial exacerbations and Anthonisen type 1 exac-
erbations [5, 13, 37, 38].
In contrast to the study of Stockley et al. [17], sputum pu-
rulence was not a predictor of bacterial exacerbation. This not
only means that patients with mucoid sputum production dur-
ing the exacerbation are known to improve without antibiotic
therapy [17], but also that patients with purulent sputum dur-
ing the exacerbation might not be candidates for antibiotic
treatment.
In conclusion, we believe that patients who present with an
exacerbation of COPD and who have a negative sputum Gram
stain result, no clinically relevant decrease in lung function
(compared with baseline measurements), and a history of !2
exacerbations of COPD in the previous year do not need ad-
ditional antibiotic treatment for an exacerbation. However, be-
fore it is implemented in clinical practice, this prediction rule
should be validated in an external population. Furthermore,
future studies are needed to determine whether other subgroups
of patients with COPD exist in whom bacteria are likely to play
an important role and for whom antibiotic treatment is thus
indicated.
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